Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
General Surgery | 12 | 2021 | 229 | 3.210 |
Why?
|
Pancreas | 7 | 2017 | 239 | 2.400 |
Why?
|
Pancreatitis, Chronic | 12 | 2021 | 49 | 2.310 |
Why?
|
Sodium-Potassium-Chloride Symporters | 7 | 2012 | 22 | 2.040 |
Why?
|
Islets of Langerhans Transplantation | 13 | 2021 | 225 | 1.760 |
Why?
|
Specialties, Surgical | 6 | 2021 | 64 | 1.720 |
Why?
|
Chlorides | 6 | 2012 | 103 | 1.700 |
Why?
|
Pneumonia, Viral | 7 | 2020 | 316 | 1.670 |
Why?
|
Coronavirus Infections | 7 | 2020 | 301 | 1.660 |
Why?
|
Surgical Procedures, Operative | 5 | 2020 | 182 | 1.580 |
Why?
|
Pancreatectomy | 15 | 2021 | 148 | 1.570 |
Why?
|
Digestive System Surgical Procedures | 6 | 2019 | 120 | 1.540 |
Why?
|
Pandemics | 10 | 2020 | 740 | 1.470 |
Why?
|
Epithelial Cells | 10 | 2012 | 669 | 1.370 |
Why?
|
Endosonography | 6 | 2020 | 96 | 1.280 |
Why?
|
Colon | 6 | 2012 | 496 | 1.210 |
Why?
|
Protein Kinase C | 7 | 2005 | 270 | 1.210 |
Why?
|
Intestinal Mucosa | 11 | 2012 | 797 | 1.210 |
Why?
|
Surgery Department, Hospital | 3 | 2020 | 42 | 1.080 |
Why?
|
Education, Medical, Graduate | 6 | 2020 | 369 | 1.070 |
Why?
|
Quaternary Ammonium Compounds | 4 | 2007 | 79 | 1.050 |
Why?
|
Pancreatitis, Acute Necrotizing | 4 | 2012 | 16 | 1.010 |
Why?
|
Gastroenterostomy | 2 | 2020 | 7 | 0.940 |
Why?
|
Pancreatic Neoplasms | 7 | 2014 | 645 | 0.930 |
Why?
|
Infection Control | 4 | 2020 | 115 | 0.930 |
Why?
|
Humans | 101 | 2024 | 86643 | 0.910 |
Why?
|
Pancreaticoduodenectomy | 7 | 2016 | 81 | 0.850 |
Why?
|
Patient Selection | 4 | 2020 | 685 | 0.820 |
Why?
|
Disaster Planning | 1 | 2021 | 24 | 0.800 |
Why?
|
Truth Disclosure | 2 | 2021 | 87 | 0.790 |
Why?
|
Checklist | 1 | 2021 | 57 | 0.780 |
Why?
|
Judgment | 1 | 2021 | 64 | 0.770 |
Why?
|
Advisory Committees | 2 | 2020 | 90 | 0.760 |
Why?
|
Education, Medical, Continuing | 1 | 2021 | 107 | 0.740 |
Why?
|
Accreditation | 1 | 2020 | 60 | 0.740 |
Why?
|
Immune Tolerance | 4 | 2010 | 337 | 0.720 |
Why?
|
National Institutes of Health (U.S.) | 3 | 2021 | 122 | 0.720 |
Why?
|
Peptic Ulcer | 1 | 2019 | 19 | 0.720 |
Why?
|
Surgical Wound Infection | 3 | 2019 | 184 | 0.710 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 57 | 0.700 |
Why?
|
Betacoronavirus | 7 | 2020 | 258 | 0.700 |
Why?
|
Health Resources | 1 | 2020 | 76 | 0.700 |
Why?
|
Quality of Health Care | 2 | 2020 | 380 | 0.700 |
Why?
|
Music | 1 | 2019 | 34 | 0.690 |
Why?
|
Protein Kinase C-epsilon | 6 | 2010 | 22 | 0.680 |
Why?
|
Clinical Decision-Making | 1 | 2021 | 257 | 0.680 |
Why?
|
Cyclic AMP | 3 | 2010 | 273 | 0.680 |
Why?
|
Gastric Outlet Obstruction | 2 | 2017 | 10 | 0.650 |
Why?
|
Tetradecanoylphorbol Acetate | 5 | 2010 | 137 | 0.630 |
Why?
|
Informed Consent | 1 | 2020 | 266 | 0.620 |
Why?
|
Decision Making | 2 | 2020 | 642 | 0.610 |
Why?
|
Spinal Cord Injuries | 1 | 2017 | 54 | 0.610 |
Why?
|
Pancreatitis | 4 | 2012 | 87 | 0.600 |
Why?
|
Electronic Health Records | 1 | 2020 | 319 | 0.590 |
Why?
|
United States | 18 | 2021 | 6672 | 0.570 |
Why?
|
Spinal Cord | 1 | 2017 | 249 | 0.560 |
Why?
|
Delivery of Health Care | 1 | 2020 | 426 | 0.540 |
Why?
|
Triage | 3 | 2020 | 108 | 0.530 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 610 | 0.510 |
Why?
|
Anastomotic Leak | 2 | 2014 | 96 | 0.500 |
Why?
|
History, 20th Century | 5 | 2021 | 312 | 0.500 |
Why?
|
Pancreatic Pseudocyst | 1 | 2014 | 9 | 0.490 |
Why?
|
Pancreatic Fistula | 2 | 2011 | 16 | 0.480 |
Why?
|
Choristoma | 1 | 2014 | 68 | 0.470 |
Why?
|
Endocytosis | 3 | 2010 | 177 | 0.470 |
Why?
|
Transplantation, Autologous | 12 | 2021 | 331 | 0.470 |
Why?
|
Peer Review | 1 | 2013 | 24 | 0.470 |
Why?
|
Gastrointestinal Motility | 1 | 2013 | 25 | 0.460 |
Why?
|
Lactones | 2 | 2003 | 28 | 0.450 |
Why?
|
Capsaicin | 1 | 2012 | 44 | 0.450 |
Why?
|
TRPV Cation Channels | 1 | 2012 | 15 | 0.440 |
Why?
|
Surgeons | 3 | 2022 | 238 | 0.440 |
Why?
|
Protein Kinase C-delta | 2 | 2010 | 26 | 0.440 |
Why?
|
Congresses as Topic | 1 | 2013 | 116 | 0.440 |
Why?
|
Solute Carrier Family 12, Member 2 | 5 | 2012 | 16 | 0.430 |
Why?
|
Adenocarcinoma | 2 | 2013 | 1169 | 0.430 |
Why?
|
Carbachol | 4 | 2005 | 34 | 0.430 |
Why?
|
Cell Line | 12 | 2012 | 2468 | 0.430 |
Why?
|
Postoperative Complications | 7 | 2017 | 2207 | 0.430 |
Why?
|
Cholangitis | 1 | 2012 | 19 | 0.420 |
Why?
|
Choledocholithiasis | 1 | 2012 | 12 | 0.420 |
Why?
|
Duodenal Diseases | 1 | 2012 | 24 | 0.420 |
Why?
|
Workload | 2 | 2020 | 128 | 0.420 |
Why?
|
Biomedical Research | 2 | 2021 | 376 | 0.410 |
Why?
|
Gastrointestinal Diseases | 1 | 2013 | 146 | 0.410 |
Why?
|
Specialty Boards | 1 | 2011 | 24 | 0.410 |
Why?
|
Diverticulum | 1 | 2012 | 44 | 0.410 |
Why?
|
Periodicals as Topic | 1 | 2013 | 168 | 0.400 |
Why?
|
Clinical Competence | 3 | 2020 | 751 | 0.400 |
Why?
|
Neoadjuvant Therapy | 4 | 2024 | 318 | 0.400 |
Why?
|
Laparoscopy | 4 | 2020 | 754 | 0.390 |
Why?
|
Colectomy | 1 | 2012 | 167 | 0.390 |
Why?
|
Blood Glucose | 4 | 2021 | 873 | 0.380 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2012 | 237 | 0.380 |
Why?
|
Cost Savings | 1 | 2010 | 66 | 0.380 |
Why?
|
Internship and Residency | 5 | 2020 | 1004 | 0.380 |
Why?
|
Pancreatic Cyst | 1 | 2010 | 28 | 0.370 |
Why?
|
Gallbladder Neoplasms | 1 | 2010 | 22 | 0.370 |
Why?
|
Career Choice | 1 | 2011 | 139 | 0.370 |
Why?
|
Bile Acids and Salts | 2 | 2011 | 61 | 0.360 |
Why?
|
Clathrin | 1 | 2009 | 29 | 0.360 |
Why?
|
Societies, Medical | 4 | 2020 | 572 | 0.350 |
Why?
|
Health Expenditures | 1 | 2010 | 86 | 0.350 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2010 | 50 | 0.350 |
Why?
|
Program Development | 1 | 2010 | 124 | 0.350 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2010 | 214 | 0.340 |
Why?
|
Universities | 3 | 2019 | 135 | 0.340 |
Why?
|
Critical Care | 3 | 2020 | 370 | 0.340 |
Why?
|
Cooperative Behavior | 1 | 2010 | 174 | 0.330 |
Why?
|
Male | 33 | 2021 | 40965 | 0.330 |
Why?
|
Female | 31 | 2024 | 44532 | 0.330 |
Why?
|
Chicago | 4 | 2020 | 1379 | 0.320 |
Why?
|
Membrane Proteins | 3 | 2011 | 1196 | 0.310 |
Why?
|
Ultrasonography, Interventional | 2 | 2020 | 121 | 0.310 |
Why?
|
Potassium Channels | 3 | 2004 | 340 | 0.310 |
Why?
|
Drainage | 3 | 2015 | 157 | 0.310 |
Why?
|
Intestinal Diseases | 2 | 2009 | 79 | 0.310 |
Why?
|
Islets of Langerhans | 3 | 2021 | 544 | 0.300 |
Why?
|
Hospital Mortality | 1 | 2009 | 349 | 0.300 |
Why?
|
Blood Proteins | 1 | 2007 | 144 | 0.300 |
Why?
|
Breast Neoplasms | 4 | 2024 | 2903 | 0.300 |
Why?
|
Muscarinic Agonists | 2 | 2005 | 23 | 0.300 |
Why?
|
Abdominal Pain | 4 | 2021 | 137 | 0.290 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2020 | 1313 | 0.290 |
Why?
|
Risk Assessment | 5 | 2020 | 2261 | 0.280 |
Why?
|
Carcinoma | 1 | 2010 | 436 | 0.280 |
Why?
|
Membrane Transport Proteins | 2 | 2005 | 166 | 0.280 |
Why?
|
Research Support as Topic | 2 | 2021 | 80 | 0.280 |
Why?
|
Insulin-Secreting Cells | 2 | 2021 | 397 | 0.280 |
Why?
|
History, 21st Century | 3 | 2021 | 175 | 0.270 |
Why?
|
Bicarbonates | 1 | 2005 | 60 | 0.270 |
Why?
|
History, 19th Century | 2 | 2021 | 59 | 0.270 |
Why?
|
Membrane Glycoproteins | 1 | 2007 | 428 | 0.260 |
Why?
|
Dogs | 4 | 2017 | 685 | 0.260 |
Why?
|
Clotrimazole | 1 | 2004 | 3 | 0.260 |
Why?
|
Charybdotoxin | 1 | 2004 | 8 | 0.260 |
Why?
|
Splenic Artery | 1 | 2004 | 11 | 0.250 |
Why?
|
Middle Aged | 22 | 2020 | 25028 | 0.250 |
Why?
|
Digestive System Abnormalities | 1 | 2004 | 13 | 0.250 |
Why?
|
Thrombin | 1 | 2004 | 61 | 0.250 |
Why?
|
Wound Healing | 2 | 2004 | 344 | 0.250 |
Why?
|
Diarrhea | 1 | 2005 | 182 | 0.250 |
Why?
|
Receptor, ErbB-2 | 3 | 2024 | 223 | 0.250 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 806 | 0.250 |
Why?
|
Aneurysm, False | 1 | 2004 | 54 | 0.240 |
Why?
|
Hemostatics | 1 | 2004 | 56 | 0.240 |
Why?
|
Schools, Medical | 1 | 2005 | 123 | 0.240 |
Why?
|
Gastric Bypass | 1 | 2005 | 110 | 0.230 |
Why?
|
Physics | 1 | 2003 | 22 | 0.230 |
Why?
|
Transplantation | 1 | 2003 | 39 | 0.230 |
Why?
|
Stents | 3 | 2020 | 377 | 0.230 |
Why?
|
Adult | 20 | 2020 | 25648 | 0.230 |
Why?
|
Necrosis | 3 | 2012 | 204 | 0.230 |
Why?
|
Collagen | 1 | 2004 | 269 | 0.220 |
Why?
|
Protein Transport | 5 | 2010 | 411 | 0.220 |
Why?
|
Docosahexaenoic Acids | 1 | 2003 | 31 | 0.220 |
Why?
|
Health Care Costs | 1 | 2005 | 238 | 0.220 |
Why?
|
Gastroenterology | 2 | 2016 | 134 | 0.220 |
Why?
|
Treatment Outcome | 14 | 2021 | 7993 | 0.220 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 879 | 0.220 |
Why?
|
Regeneration | 1 | 2003 | 143 | 0.210 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2004 | 379 | 0.210 |
Why?
|
Ion Channels | 1 | 2004 | 246 | 0.210 |
Why?
|
Recombinant Fusion Proteins | 1 | 2024 | 557 | 0.210 |
Why?
|
Reoperation | 2 | 2017 | 597 | 0.210 |
Why?
|
Obesity, Morbid | 1 | 2005 | 225 | 0.210 |
Why?
|
Tight Junctions | 1 | 2003 | 149 | 0.210 |
Why?
|
Isoenzymes | 1 | 2002 | 271 | 0.210 |
Why?
|
History, 15th Century | 1 | 2021 | 6 | 0.210 |
Why?
|
Biotinylation | 2 | 2012 | 41 | 0.210 |
Why?
|
History, 16th Century | 1 | 2021 | 9 | 0.210 |
Why?
|
History, 17th Century | 1 | 2021 | 12 | 0.210 |
Why?
|
History, Medieval | 1 | 2021 | 11 | 0.210 |
Why?
|
Embolization, Therapeutic | 1 | 2004 | 238 | 0.210 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 2438 | 0.200 |
Why?
|
History, 18th Century | 1 | 2021 | 23 | 0.200 |
Why?
|
Head Injuries, Penetrating | 1 | 2022 | 54 | 0.200 |
Why?
|
Medicine | 1 | 2022 | 89 | 0.200 |
Why?
|
History, Ancient | 1 | 2021 | 74 | 0.200 |
Why?
|
Information Services | 1 | 2001 | 23 | 0.200 |
Why?
|
Intestines | 1 | 2004 | 411 | 0.200 |
Why?
|
Immunohistochemistry | 3 | 2012 | 1753 | 0.200 |
Why?
|
Awards and Prizes | 1 | 2021 | 36 | 0.190 |
Why?
|
Societies, Scientific | 1 | 2001 | 44 | 0.190 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 3 | 2007 | 78 | 0.190 |
Why?
|
Geriatric Assessment | 2 | 2014 | 166 | 0.190 |
Why?
|
Critical Illness | 1 | 2003 | 294 | 0.190 |
Why?
|
Anastomosis, Roux-en-Y | 3 | 2012 | 26 | 0.190 |
Why?
|
Risk | 2 | 2020 | 674 | 0.190 |
Why?
|
Brain Injuries, Traumatic | 1 | 2022 | 86 | 0.190 |
Why?
|
Symptom Assessment | 1 | 2020 | 65 | 0.190 |
Why?
|
Up-Regulation | 1 | 2003 | 712 | 0.190 |
Why?
|
Surveys and Questionnaires | 4 | 2020 | 2501 | 0.190 |
Why?
|
Antibody Formation | 1 | 2020 | 171 | 0.180 |
Why?
|
Animals | 14 | 2017 | 26582 | 0.180 |
Why?
|
Uncertainty | 1 | 2020 | 71 | 0.180 |
Why?
|
Academic Medical Centers | 4 | 2022 | 379 | 0.180 |
Why?
|
Efficiency, Organizational | 1 | 2020 | 58 | 0.180 |
Why?
|
Hydrogen-Ion Concentration | 3 | 2007 | 493 | 0.180 |
Why?
|
Fatty Liver | 1 | 2021 | 125 | 0.180 |
Why?
|
Quality of Life | 3 | 2017 | 1585 | 0.170 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 1169 | 0.170 |
Why?
|
Antibodies, Viral | 1 | 2020 | 293 | 0.170 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2002 | 683 | 0.170 |
Why?
|
Elective Surgical Procedures | 1 | 2020 | 116 | 0.170 |
Why?
|
Pseudomonas aeruginosa | 2 | 2011 | 194 | 0.170 |
Why?
|
Operating Rooms | 1 | 2020 | 126 | 0.170 |
Why?
|
Colforsin | 2 | 2012 | 74 | 0.170 |
Why?
|
Students | 1 | 2020 | 147 | 0.170 |
Why?
|
Robotics | 1 | 2022 | 267 | 0.170 |
Why?
|
Rats, Sprague-Dawley | 4 | 2017 | 1219 | 0.170 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2020 | 159 | 0.170 |
Why?
|
Health Equity | 1 | 2020 | 77 | 0.160 |
Why?
|
Physician's Role | 1 | 2020 | 179 | 0.160 |
Why?
|
Fasting | 1 | 2018 | 161 | 0.160 |
Why?
|
Tissue and Organ Procurement | 1 | 2022 | 311 | 0.160 |
Why?
|
Health Status | 1 | 2020 | 360 | 0.160 |
Why?
|
Internet | 1 | 2020 | 312 | 0.160 |
Why?
|
Tomography, X-Ray Computed | 4 | 2014 | 2601 | 0.160 |
Why?
|
Blotting, Western | 2 | 2012 | 782 | 0.160 |
Why?
|
Reperfusion Injury | 2 | 2011 | 131 | 0.150 |
Why?
|
Gene Expression Regulation | 2 | 2005 | 1920 | 0.150 |
Why?
|
Contraindications | 2 | 2014 | 72 | 0.150 |
Why?
|
Trastuzumab | 3 | 2024 | 68 | 0.150 |
Why?
|
Sepsis | 2 | 2011 | 306 | 0.150 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 636 | 0.150 |
Why?
|
Patient Readmission | 2 | 2017 | 329 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2012 | 1961 | 0.140 |
Why?
|
Medical Staff, Hospital | 1 | 2016 | 107 | 0.130 |
Why?
|
Cultural Diversity | 1 | 2016 | 51 | 0.130 |
Why?
|
Cells, Cultured | 4 | 2005 | 2818 | 0.130 |
Why?
|
Abdominal Abscess | 1 | 2015 | 22 | 0.130 |
Why?
|
Pain, Postoperative | 1 | 2017 | 240 | 0.130 |
Why?
|
Tissue Preservation | 1 | 2015 | 14 | 0.130 |
Why?
|
Escherichia coli Infections | 1 | 2015 | 35 | 0.130 |
Why?
|
Follow-Up Studies | 5 | 2019 | 3640 | 0.130 |
Why?
|
Sodium-Bicarbonate Symporters | 2 | 2005 | 7 | 0.130 |
Why?
|
Survival Analysis | 4 | 2014 | 1538 | 0.130 |
Why?
|
Surgery, Computer-Assisted | 2 | 2017 | 99 | 0.120 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2020 | 930 | 0.120 |
Why?
|
Child | 6 | 2022 | 6927 | 0.120 |
Why?
|
Pancreatic Hormones | 1 | 2014 | 15 | 0.120 |
Why?
|
Referral and Consultation | 1 | 2016 | 328 | 0.120 |
Why?
|
Endoscopy | 2 | 2017 | 332 | 0.120 |
Why?
|
Incidence | 3 | 2019 | 1577 | 0.120 |
Why?
|
Calcium | 2 | 2012 | 1156 | 0.120 |
Why?
|
Insulin | 4 | 2014 | 1160 | 0.120 |
Why?
|
Microscopy, Fluorescence | 3 | 2011 | 425 | 0.120 |
Why?
|
Cholangitis, Sclerosing | 1 | 2013 | 52 | 0.120 |
Why?
|
Risk Factors | 4 | 2017 | 5417 | 0.110 |
Why?
|
Bryostatins | 2 | 2003 | 15 | 0.110 |
Why?
|
Databases, Factual | 3 | 2017 | 814 | 0.110 |
Why?
|
Cell Polarity | 2 | 2005 | 115 | 0.110 |
Why?
|
California | 1 | 2013 | 138 | 0.110 |
Why?
|
Hormone Replacement Therapy | 1 | 2014 | 77 | 0.110 |
Why?
|
Macrolides | 2 | 2003 | 31 | 0.110 |
Why?
|
Diterpenes | 1 | 2012 | 20 | 0.110 |
Why?
|
Acrylamides | 1 | 2012 | 30 | 0.110 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2014 | 153 | 0.110 |
Why?
|
Time Factors | 4 | 2019 | 5210 | 0.110 |
Why?
|
Pancreatic Diseases | 1 | 2012 | 52 | 0.110 |
Why?
|
Electric Conductivity | 1 | 2012 | 144 | 0.110 |
Why?
|
Hypersensitivity | 2 | 2007 | 154 | 0.110 |
Why?
|
Aged | 9 | 2020 | 18415 | 0.110 |
Why?
|
Kidney | 3 | 2009 | 1241 | 0.110 |
Why?
|
Abscess | 1 | 2012 | 91 | 0.110 |
Why?
|
Antibiotic Prophylaxis | 2 | 2011 | 71 | 0.110 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 1 | 2012 | 76 | 0.110 |
Why?
|
Cell Membrane | 3 | 2005 | 666 | 0.110 |
Why?
|
Jejunum | 1 | 2012 | 79 | 0.100 |
Why?
|
Acute Disease | 1 | 2014 | 826 | 0.100 |
Why?
|
Duodenum | 1 | 2012 | 100 | 0.100 |
Why?
|
Enzyme Inhibitors | 3 | 2004 | 639 | 0.100 |
Why?
|
Healthcare Disparities | 1 | 2016 | 371 | 0.100 |
Why?
|
Chronic Pain | 1 | 2013 | 145 | 0.100 |
Why?
|
Antineoplastic Agents | 1 | 2002 | 2360 | 0.100 |
Why?
|
Debridement | 1 | 2011 | 56 | 0.100 |
Why?
|
Conflict of Interest | 1 | 2011 | 67 | 0.100 |
Why?
|
Mice, Inbred C57BL | 3 | 2012 | 3092 | 0.100 |
Why?
|
Pseudomonas Infections | 1 | 2011 | 95 | 0.100 |
Why?
|
Research | 2 | 2003 | 253 | 0.100 |
Why?
|
Regional Health Planning | 1 | 2010 | 13 | 0.100 |
Why?
|
Laparoscopes | 1 | 2011 | 15 | 0.100 |
Why?
|
National Health Programs | 1 | 2010 | 20 | 0.100 |
Why?
|
Dopamine | 1 | 2012 | 275 | 0.100 |
Why?
|
Cost Control | 1 | 2010 | 44 | 0.100 |
Why?
|
Polyethylene Glycols | 2 | 2011 | 363 | 0.100 |
Why?
|
Recurrence | 1 | 2014 | 1139 | 0.100 |
Why?
|
Adolescent | 8 | 2019 | 8981 | 0.100 |
Why?
|
Algorithms | 2 | 2012 | 1830 | 0.100 |
Why?
|
Cystadenoma, Mucinous | 1 | 2010 | 7 | 0.100 |
Why?
|
Cystadenoma, Serous | 1 | 2010 | 15 | 0.090 |
Why?
|
Cystadenoma, Papillary | 1 | 2010 | 8 | 0.090 |
Why?
|
Neoplasm Staging | 2 | 2020 | 1939 | 0.090 |
Why?
|
Ions | 1 | 2010 | 74 | 0.090 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 30 | 0.090 |
Why?
|
Polymers | 1 | 2011 | 202 | 0.090 |
Why?
|
Personal Protective Equipment | 2 | 2020 | 32 | 0.090 |
Why?
|
Financing, Government | 1 | 2010 | 23 | 0.090 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2010 | 45 | 0.090 |
Why?
|
Paclitaxel | 2 | 2024 | 460 | 0.090 |
Why?
|
Signal Transduction | 4 | 2005 | 3241 | 0.090 |
Why?
|
DNA, Complementary | 2 | 2007 | 393 | 0.090 |
Why?
|
Intestine, Small | 1 | 2011 | 303 | 0.090 |
Why?
|
Radiation Injuries, Experimental | 1 | 2009 | 41 | 0.090 |
Why?
|
Protein Isoforms | 1 | 2010 | 270 | 0.090 |
Why?
|
Membrane Microdomains | 1 | 2009 | 54 | 0.090 |
Why?
|
Autoantigens | 1 | 2010 | 127 | 0.090 |
Why?
|
United States Food and Drug Administration | 1 | 2010 | 127 | 0.090 |
Why?
|
Radiation-Protective Agents | 1 | 2009 | 96 | 0.090 |
Why?
|
RNA Interference | 1 | 2010 | 369 | 0.090 |
Why?
|
Adenoviridae | 1 | 2010 | 345 | 0.090 |
Why?
|
Ileum | 1 | 2009 | 159 | 0.080 |
Why?
|
Liver Neoplasms | 2 | 2007 | 736 | 0.080 |
Why?
|
Racism | 2 | 2021 | 81 | 0.080 |
Why?
|
Doxorubicin | 2 | 2020 | 295 | 0.080 |
Why?
|
Liver | 2 | 2012 | 1230 | 0.080 |
Why?
|
Professional Autonomy | 2 | 2020 | 41 | 0.080 |
Why?
|
Reference Values | 2 | 2011 | 674 | 0.080 |
Why?
|
Rubidium Radioisotopes | 1 | 2007 | 4 | 0.080 |
Why?
|
Methylamines | 1 | 2007 | 5 | 0.080 |
Why?
|
Guideline Adherence | 1 | 2010 | 223 | 0.080 |
Why?
|
Chloride Channels | 2 | 2005 | 42 | 0.080 |
Why?
|
Positron-Emission Tomography | 1 | 2010 | 329 | 0.080 |
Why?
|
Endoscopy, Digestive System | 1 | 2008 | 65 | 0.080 |
Why?
|
Biological Transport, Active | 1 | 2007 | 102 | 0.080 |
Why?
|
Severity of Illness Index | 3 | 2017 | 1801 | 0.080 |
Why?
|
Jejunostomy | 1 | 2007 | 14 | 0.080 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2010 | 295 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2010 | 429 | 0.080 |
Why?
|
Rats | 4 | 2009 | 3990 | 0.070 |
Why?
|
Length of Stay | 2 | 2014 | 702 | 0.070 |
Why?
|
Young Adult | 5 | 2019 | 5976 | 0.070 |
Why?
|
Plasmids | 1 | 2007 | 287 | 0.070 |
Why?
|
Surgical Instruments | 2 | 2005 | 57 | 0.070 |
Why?
|
Adenosine Triphosphatases | 1 | 2007 | 153 | 0.070 |
Why?
|
Retrospective Studies | 6 | 2021 | 8489 | 0.070 |
Why?
|
Glucose | 1 | 2009 | 638 | 0.070 |
Why?
|
Immunization | 1 | 2007 | 158 | 0.070 |
Why?
|
Protein Kinase C-alpha | 2 | 2004 | 27 | 0.070 |
Why?
|
Survival Rate | 2 | 2014 | 1863 | 0.070 |
Why?
|
Carbazoles | 2 | 2004 | 51 | 0.070 |
Why?
|
Enterohepatic Circulation | 1 | 2005 | 3 | 0.070 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2005 | 3 | 0.070 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 746 | 0.070 |
Why?
|
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2005 | 17 | 0.070 |
Why?
|
Antiporters | 1 | 2005 | 18 | 0.070 |
Why?
|
Stilbenes | 1 | 2005 | 25 | 0.070 |
Why?
|
Autoimmunity | 2 | 2010 | 160 | 0.070 |
Why?
|
Biological Transport | 2 | 2004 | 396 | 0.070 |
Why?
|
Intestinal Absorption | 1 | 2005 | 124 | 0.070 |
Why?
|
Blotting, Northern | 1 | 2005 | 256 | 0.070 |
Why?
|
Ohio | 1 | 2005 | 37 | 0.070 |
Why?
|
Membrane Potentials | 2 | 2004 | 435 | 0.060 |
Why?
|
Mesenteric Veins | 1 | 2005 | 34 | 0.060 |
Why?
|
Myristoylated Alanine-Rich C Kinase Substrate | 1 | 2004 | 3 | 0.060 |
Why?
|
Cholinergic Agonists | 1 | 2004 | 9 | 0.060 |
Why?
|
Ischemic Preconditioning | 1 | 2005 | 37 | 0.060 |
Why?
|
Dissection | 1 | 2005 | 42 | 0.060 |
Why?
|
Injections, Intralesional | 1 | 2004 | 22 | 0.060 |
Why?
|
Barium | 1 | 2004 | 31 | 0.060 |
Why?
|
Phosphorylation | 2 | 2004 | 1106 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2014 | 6509 | 0.060 |
Why?
|
Age Factors | 1 | 2009 | 1851 | 0.060 |
Why?
|
Disease-Free Survival | 2 | 2020 | 1204 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2007 | 241 | 0.060 |
Why?
|
Receptor, TIE-2 | 1 | 2024 | 15 | 0.060 |
Why?
|
Indoles | 2 | 2004 | 318 | 0.060 |
Why?
|
Drug Combinations | 1 | 2004 | 224 | 0.060 |
Why?
|
Neutrophil Infiltration | 1 | 2004 | 28 | 0.060 |
Why?
|
Myosin Light Chains | 1 | 2003 | 29 | 0.060 |
Why?
|
Salmonella typhimurium | 1 | 2004 | 32 | 0.060 |
Why?
|
Suture Techniques | 1 | 2005 | 135 | 0.060 |
Why?
|
Mice | 3 | 2012 | 11352 | 0.060 |
Why?
|
Microscopy, Electron | 1 | 2004 | 503 | 0.060 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2005 | 108 | 0.060 |
Why?
|
Chlorine | 1 | 2003 | 8 | 0.060 |
Why?
|
Biliary Fistula | 1 | 2003 | 11 | 0.060 |
Why?
|
Stimulation, Chemical | 1 | 2003 | 63 | 0.060 |
Why?
|
Radioisotopes | 1 | 2003 | 45 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2004 | 293 | 0.060 |
Why?
|
Quantum Theory | 1 | 2003 | 28 | 0.060 |
Why?
|
Dinoprostone | 1 | 2003 | 69 | 0.060 |
Why?
|
Ultrasonics | 1 | 2003 | 38 | 0.060 |
Why?
|
Growth Substances | 1 | 2003 | 80 | 0.060 |
Why?
|
Chimera | 1 | 2003 | 56 | 0.060 |
Why?
|
Zonula Occludens-2 Protein | 1 | 2003 | 11 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2010 | 2705 | 0.060 |
Why?
|
Claudin-1 | 1 | 2003 | 17 | 0.060 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2003 | 83 | 0.060 |
Why?
|
Professional Practice | 1 | 2003 | 46 | 0.060 |
Why?
|
Focal Adhesions | 1 | 2003 | 69 | 0.060 |
Why?
|
Occludin | 1 | 2003 | 66 | 0.060 |
Why?
|
Tritium | 1 | 2002 | 133 | 0.060 |
Why?
|
Ammonia | 1 | 2003 | 37 | 0.060 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2002 | 43 | 0.060 |
Why?
|
Thapsigargin | 1 | 2002 | 55 | 0.060 |
Why?
|
Mannitol | 1 | 2002 | 49 | 0.060 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2002 | 88 | 0.060 |
Why?
|
Cell Membrane Permeability | 1 | 2003 | 119 | 0.060 |
Why?
|
Electric Impedance | 1 | 2003 | 104 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 1036 | 0.050 |
Why?
|
Health Care Surveys | 2 | 2016 | 278 | 0.050 |
Why?
|
Tumor Cells, Cultured | 1 | 2004 | 1041 | 0.050 |
Why?
|
Epithelium | 1 | 2003 | 319 | 0.050 |
Why?
|
Iodine Radioisotopes | 1 | 2002 | 134 | 0.050 |
Why?
|
Carcinogens | 1 | 2002 | 108 | 0.050 |
Why?
|
Microfilament Proteins | 1 | 2004 | 208 | 0.050 |
Why?
|
Radiography | 1 | 2004 | 813 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2024 | 361 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2005 | 454 | 0.050 |
Why?
|
Cystic Fibrosis | 1 | 2003 | 112 | 0.050 |
Why?
|
Potassium | 1 | 2003 | 281 | 0.050 |
Why?
|
Drug Interactions | 1 | 2002 | 248 | 0.050 |
Why?
|
Specialization | 1 | 2022 | 65 | 0.050 |
Why?
|
Liver Diseases | 1 | 2004 | 238 | 0.050 |
Why?
|
Receptors, Cell Surface | 1 | 2003 | 286 | 0.050 |
Why?
|
Education, Medical | 1 | 2005 | 233 | 0.050 |
Why?
|
Ultrasonography | 1 | 2004 | 695 | 0.050 |
Why?
|
Cell Division | 1 | 2003 | 696 | 0.050 |
Why?
|
Resuscitation | 1 | 2022 | 100 | 0.050 |
Why?
|
Cytoskeleton | 1 | 2002 | 193 | 0.050 |
Why?
|
Body Mass Index | 1 | 2005 | 770 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2003 | 372 | 0.050 |
Why?
|
Antigens, CD | 1 | 2002 | 458 | 0.050 |
Why?
|
Immunization, Passive | 1 | 2020 | 71 | 0.050 |
Why?
|
Cell Movement | 1 | 2004 | 758 | 0.050 |
Why?
|
Bridged-Ring Compounds | 1 | 2020 | 13 | 0.050 |
Why?
|
Social Problems | 1 | 2020 | 10 | 0.050 |
Why?
|
Bacterial Adhesion | 2 | 2011 | 84 | 0.050 |
Why?
|
Organizational Innovation | 1 | 2020 | 41 | 0.050 |
Why?
|
Sexism | 1 | 2021 | 51 | 0.050 |
Why?
|
Epidemics | 1 | 2020 | 33 | 0.050 |
Why?
|
Education, Distance | 1 | 2020 | 25 | 0.050 |
Why?
|
Computer-Assisted Instruction | 1 | 2020 | 43 | 0.050 |
Why?
|
Neurosurgical Procedures | 1 | 2022 | 213 | 0.050 |
Why?
|
Taxoids | 1 | 2020 | 129 | 0.050 |
Why?
|
Antibodies, Neutralizing | 1 | 2020 | 112 | 0.050 |
Why?
|
Colonic Neoplasms | 1 | 2004 | 556 | 0.050 |
Why?
|
Virulence | 2 | 2011 | 271 | 0.050 |
Why?
|
Patient Care Team | 1 | 2022 | 280 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2004 | 1991 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2020 | 299 | 0.040 |
Why?
|
Cytokines | 1 | 2003 | 776 | 0.040 |
Why?
|
Actins | 1 | 2002 | 451 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2007 | 938 | 0.040 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2020 | 93 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2003 | 384 | 0.040 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2019 | 26 | 0.040 |
Why?
|
Hypoxia | 1 | 2004 | 641 | 0.040 |
Why?
|
Cross Infection | 1 | 2020 | 141 | 0.040 |
Why?
|
Receptors, Steroid | 1 | 2019 | 42 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2020 | 456 | 0.040 |
Why?
|
C-Peptide | 1 | 2018 | 174 | 0.040 |
Why?
|
Violence | 1 | 2020 | 143 | 0.040 |
Why?
|
Health Personnel | 1 | 2020 | 202 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 859 | 0.040 |
Why?
|
Prospective Studies | 2 | 2018 | 4213 | 0.040 |
Why?
|
Hypoglycemic Agents | 2 | 2014 | 378 | 0.040 |
Why?
|
Bacterial Proteins | 1 | 2004 | 864 | 0.040 |
Why?
|
Sex Factors | 1 | 2021 | 1054 | 0.040 |
Why?
|
Organ Transplantation | 1 | 2001 | 265 | 0.040 |
Why?
|
Risk Adjustment | 1 | 2017 | 39 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 322 | 0.040 |
Why?
|
Learning | 1 | 2020 | 280 | 0.040 |
Why?
|
Stress, Psychological | 1 | 2020 | 313 | 0.040 |
Why?
|
Propensity Score | 1 | 2017 | 136 | 0.040 |
Why?
|
Pain Management | 1 | 2017 | 127 | 0.040 |
Why?
|
Cultural Competency | 1 | 2016 | 21 | 0.030 |
Why?
|
Models, Biological | 1 | 2003 | 1749 | 0.030 |
Why?
|
Palliative Care | 1 | 2017 | 257 | 0.030 |
Why?
|
Program Evaluation | 1 | 2016 | 297 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2016 | 319 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 1621 | 0.030 |
Why?
|
Anastomosis, Surgical | 1 | 2016 | 267 | 0.030 |
Why?
|
Robotic Surgical Procedures | 1 | 2020 | 267 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2019 | 589 | 0.030 |
Why?
|
Educational Measurement | 1 | 2016 | 225 | 0.030 |
Why?
|
Narcotics | 1 | 2014 | 69 | 0.030 |
Why?
|
Apoptosis | 2 | 2011 | 1683 | 0.030 |
Why?
|
Frail Elderly | 1 | 2014 | 71 | 0.030 |
Why?
|
Quality Improvement | 1 | 2017 | 428 | 0.030 |
Why?
|
Asthma | 1 | 2001 | 955 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2013 | 190 | 0.030 |
Why?
|
Electrophysiology | 2 | 2004 | 401 | 0.030 |
Why?
|
Illinois | 1 | 2014 | 462 | 0.030 |
Why?
|
Hepatectomy | 2 | 2004 | 166 | 0.030 |
Why?
|
Deoxycholic Acid | 1 | 2011 | 10 | 0.030 |
Why?
|
Bacterial Translocation | 1 | 2011 | 26 | 0.030 |
Why?
|
Financial Support | 1 | 2011 | 7 | 0.030 |
Why?
|
Phenols | 1 | 2011 | 40 | 0.030 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2011 | 28 | 0.030 |
Why?
|
Caco-2 Cells | 1 | 2011 | 123 | 0.030 |
Why?
|
Benzhydryl Compounds | 1 | 2011 | 48 | 0.030 |
Why?
|
Zonula Occludens-1 Protein | 1 | 2011 | 70 | 0.030 |
Why?
|
Caspase 3 | 1 | 2011 | 159 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2013 | 996 | 0.020 |
Why?
|
Random Allocation | 1 | 2011 | 332 | 0.020 |
Why?
|
Organizational Policy | 1 | 2011 | 55 | 0.020 |
Why?
|
Chronic Disease | 2 | 2005 | 971 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 364 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2011 | 254 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2011 | 170 | 0.020 |
Why?
|
Clone Cells | 1 | 2010 | 213 | 0.020 |
Why?
|
Leadership | 1 | 2011 | 134 | 0.020 |
Why?
|
Molecular Weight | 1 | 2009 | 332 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 860 | 0.020 |
Why?
|
Ethics, Medical | 1 | 2011 | 306 | 0.020 |
Why?
|
Vaccination | 1 | 2010 | 254 | 0.020 |
Why?
|
Administration, Oral | 1 | 2009 | 684 | 0.020 |
Why?
|
Cholesterol | 1 | 2009 | 356 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2007 | 90 | 0.020 |
Why?
|
Colitis, Ulcerative | 1 | 2013 | 711 | 0.020 |
Why?
|
Prognosis | 1 | 2014 | 3679 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 865 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2010 | 1823 | 0.020 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2005 | 62 | 0.020 |
Why?
|
Acidosis, Renal Tubular | 1 | 2005 | 11 | 0.020 |
Why?
|
Mesenteric Artery, Superior | 1 | 2005 | 19 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2011 | 2232 | 0.020 |
Why?
|
Immunotherapy | 1 | 2010 | 629 | 0.020 |
Why?
|
RNA, Complementary | 1 | 2004 | 8 | 0.020 |
Why?
|
Xenopus laevis | 1 | 2005 | 137 | 0.020 |
Why?
|
Kidney Tubules, Proximal | 1 | 2005 | 61 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2010 | 567 | 0.020 |
Why?
|
Phenylalanine | 1 | 2004 | 37 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 2010 | 582 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2004 | 116 | 0.020 |
Why?
|
Xenopus | 1 | 2004 | 125 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2010 | 1578 | 0.020 |
Why?
|
Membranes | 1 | 2004 | 36 | 0.020 |
Why?
|
Cytoplasm | 1 | 2005 | 281 | 0.020 |
Why?
|
Oocytes | 1 | 2005 | 221 | 0.020 |
Why?
|
Subcellular Fractions | 1 | 2004 | 93 | 0.020 |
Why?
|
Integrin beta1 | 1 | 2003 | 33 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2004 | 279 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 1565 | 0.010 |
Why?
|
Stress Fibers | 1 | 2003 | 23 | 0.010 |
Why?
|
Ligation | 1 | 2003 | 51 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2005 | 692 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2004 | 290 | 0.010 |
Why?
|
Microscopy, Confocal | 1 | 2004 | 268 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2005 | 276 | 0.010 |
Why?
|
Gene Deletion | 1 | 2004 | 329 | 0.010 |
Why?
|
Ion Transport | 1 | 2003 | 81 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2004 | 439 | 0.010 |
Why?
|
Adenosine Triphosphate | 1 | 2003 | 314 | 0.010 |
Why?
|
Transfection | 1 | 2004 | 896 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 736 | 0.010 |
Why?
|
Pain Measurement | 1 | 2003 | 321 | 0.010 |
Why?
|
Intraoperative Complications | 1 | 2003 | 185 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2004 | 1014 | 0.010 |
Why?
|
Pain | 1 | 2003 | 391 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2005 | 413 | 0.010 |
Why?
|
Peptides | 1 | 2003 | 639 | 0.010 |
Why?
|
Biopsy | 1 | 2004 | 1163 | 0.010 |
Why?
|
Cohort Studies | 1 | 2005 | 2767 | 0.010 |
Why?
|
DNA | 1 | 2004 | 1294 | 0.010 |
Why?
|
Mutation | 1 | 2004 | 3968 | 0.010 |
Why?
|